These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29563339)

  • 1. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.
    Vaught AJ; Braunstein EM; Jasem J; Yuan X; Makhlin I; Eloundou S; Baines AC; Merrill SA; Chaturvedi S; Blakemore K; Sperati CJ; Brodsky RA
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Complement Activation and Decreased ADAMTS13 Activity Are Associated with Genetic Susceptibility in Patients with Preeclampsia/HELLP Syndrome Compared to Healthy Pregnancies: An Observational Case-Controlled Study.
    Venou TM; Vetsiou E; Varelas C; Daniilidis A; Psarras K; Koravou EE; Koutra M; Touloumenidou T; Tsolakidis V; Papalexandri A; Minti F; Mandala E; Dinas K; Vlachaki E; Gavriilaki E
    J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.
    Sheridan D; Yu ZX; Zhang Y; Patel R; Sun F; Lasaro MA; Bouchard K; Andrien B; Marozsan A; Wang Y; Tamburini P
    PLoS One; 2018; 13(4):e0195909. PubMed ID: 29649283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.
    Vigna E; Petrungaro A; Perri A; Terzi D; Recchia AG; Mendicino F; La Russa A; Bossio S; De Stefano L; Zinno F; Bonofiglio R; Morabito F; Gentile M
    Transfus Apher Sci; 2018 Apr; 57(2):247-249. PubMed ID: 29567368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
    Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
    Intern Med J; 2018 Jun; 48(6):624-636. PubMed ID: 29582550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.
    Fidan K; Göknar N; Gülhan B; Melek E; Yıldırım ZY; Baskın E; Hayran M; Gülleroglu K; Özçakar ZB; Ozaltin F; Soylemezoglu O
    Pediatr Nephrol; 2018 Aug; 33(8):1395-1403. PubMed ID: 29610995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic analysis of the complement pathway in C3 glomerulopathy.
    Zhao W; Ding Y; Lu J; Zhang T; Chen D; Zhang H; Zeng C; Liu Z; Chen H
    Nephrol Dial Transplant; 2018 Nov; 33(11):1919-1927. PubMed ID: 29566171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical hemolytic uremic syndrome and eculizumab therapy in children.
    Kim SH; Kim HY; Kim SY
    Korean J Pediatr; 2018 Feb; 61(2):37-42. PubMed ID: 29563942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H (
    Cantsilieris S; Nelson BJ; Huddleston J; Baker C; Harshman L; Penewit K; Munson KM; Sorensen M; Welch AE; Dang V; Grassmann F; Richardson AJ; Guymer RH; Graves-Lindsay TA; Wilson RK; Weber BHF; Baird PN; Allikmets R; Eichler EE
    Proc Natl Acad Sci U S A; 2018 May; 115(19):E4433-E4442. PubMed ID: 29686068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
    Reher D; Fuhrmann V; Kluge S; Nierhaus A
    Vaccine; 2018 May; 36(19):2507-2509. PubMed ID: 29631884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.
    Mihai S; Hirose M; Wang Y; Thurman JM; Holers VM; Morgan BP; Köhl J; Zillikens D; Ludwig RJ; Nimmerjahn F
    Front Immunol; 2018; 9():535. PubMed ID: 29616034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement Factor D protects mice from ethanol-induced inflammation and liver injury.
    McCullough RL; McMullen MR; Sheehan MM; Poulsen KL; Roychowdhury S; Chiang DJ; Pritchard MT; Caballeria J; Nagy LE
    Am J Physiol Gastrointest Liver Physiol; 2018 Jul; 315(1):G66-G79. PubMed ID: 29597356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.
    Bajwa R; DePalma JA; Khan T; Cheema A; Kalathil SA; Hossain MA; Haroon A; Madhurima A; Zheng M; Nayer A; Asif A
    Case Rep Nephrol Dial; 2018; 8(1):25-34. PubMed ID: 29594148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neisseria elongata infection associated with complement inhibition during treatment of paroxysmal nocturnal haemoglobinuria.
    Benz R; Krause M; Majer S; Taverna C; Herzog K
    Br J Haematol; 2018 Aug; 182(3):318. PubMed ID: 29676447
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical hemolytic uremic syndrome: A monocentric adult Tunisian study and review of literature.
    Kherder-Elfekih R; Hajji M; Fatma LB; Jebali H; Mami I; Smaoui W; Krid M; Rais L; Beji S; Zouaghi K; Sellami-Kallel M
    Saudi J Kidney Dis Transpl; 2018; 29(2):297-302. PubMed ID: 29657196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical hemolytic uremic syndrome: Laboratory characteristics, complement-amplifying conditions, renal biopsy, and genetic mutations.
    Hossain MA; Cheema A; Kalathil S; Bajwa R; Costanzo EJ; Cosentino J; Cheng J; Vachharajani T; Asif A
    Saudi J Kidney Dis Transpl; 2018; 29(2):276-283. PubMed ID: 29657193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in
    Khandelwal P; Birla S; Bhatia D; Puraswani M; Saini H; Sinha A; Hari P; Sharma A; Bagga A
    Clin Kidney J; 2018 Apr; 11(2):198-203. PubMed ID: 29644059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.